Issues
-
Cover Image
Cover Image
The factors that impact the function of invariant natural killer T (iNKT) cells in cancer are not fully elucidated. Zhang and Chen et al. demonstrate that antigen priming of iNKT cells leads to metabolic and epigenetic remodeling. These alterations endow iNKT cells with limited ability to produce cytokines but high cytotoxicity. Mechanistically, shifts in cellular metabolism prevent T-cell receptor signaling, explaining the impaired cytokine production. Increased cytotoxicity is independent of the metabolic changes and is driven by epigenetic alterations, leading to increased granzyme expression. Pharmacological rescue of iNKT-cell metabolism enhances their antitumor responses, highlighting a potential strategy to boost antitumor immunity. Read more in this issue on page 1598. Original image from Fig. 4H. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We're Reading
In the Spotlight
Commentary
Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium
Review
Priority Brief
Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy
The authors show that differences in the cytokine profiles of transgenic cellular immunotherapies for solid tumors have implications for therapeutic efficacy. These differences should be considered when developing future generations of cellular therapies to augment clinical response rates.
Research Articles
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy
The impact of antigen priming–induced metabolic and epigenetic alterations on iNKT-cell function is revealed. The data provide a deeper understanding of how metabolic wiring affects antitumor responses and highlight potential approaches to enhance efficacy of iNKT cell–based immunotherapies.
A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in Cancer
A metabolic CRISPR–Cas9 screen reveals the important role of fucosylation in the suppressive function of Tregs. Measuring fucosylation in Tregs has the potential to aid in the discovery of relevant prognostic markers for cancer patients.
Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1− Dysfunctional State
Understanding how tumor-antigen type (tumor-specific versus self/shared) determines T-cell states could provide insights into responses to ICB. The authors show SSA-reactive CD8+ T cells enter and persist in a previously undescribed TCF1+PD1− memory-like state, lacking effector function.
Antitumor Immune Responses in B2M-Deficient Cancers
By studying how antitumor immune responses can be mediated against cancers that are B2M-deficient, and therefore cannot be recognized by cytotoxic CD8+ T cells, the authors provide new understanding of the mechanism of action of ICB therapies.
Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
The authors explore the therapeutic potential of VISTA in bladder cancer, finding it is mainly expressed on macrophages and predicts poor patient prognosis. Preclinical analyses identify the underlying mechanisms and suggest combining a VISTA-specific mAb and TLR3-specific adjuvant.
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma
Using a hybrid sequencing approach, SF3B1-independent alternative splicing events and novel isoforms in uveal melanoma are identified. These neoepitopes are immunogenic and can activate antitumor T-cell responses, highlighting them as potential therapeutic targets in uveal melanoma.
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.